Table 1

Selected ongoing studies using checkpoint blockade immunotherapy in definitive treatment of locally advanced cervical cancer

NCT identifierTitlePhasePlanned enrollmentPrimary endpoint(s)
NCT03830866Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)III770Progression-free survival
NCT04221945Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)III980Progression-free and overall survival
NCT03612791Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab (ATEZOLACC)II189Progression-free survival
NCT02635360Pembrolizumab and Chemoradiation Treatment for Advanced Cervical CancerII88Change in immunologic markers
NCT03833479TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemoradiation (ATOMICC)II132Progression-free survival
NCT03738228Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node-Positive Stage IB2, II, IIIB, or IVA Cervical CancerI40Clonal expansion of T-cell receptors
NCT03298893Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)I21Dose-limiting toxicity